AHL
HRTX icon

Abel Hall LLC’s Heron Therapeutics HRTX Stock Holding History

Abel Hall LLC’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.5K Sell
16,907
-29,269
-63% -$33.9K ﹤0.01% 798
2025
Q4 		$60K Buy
+46,176
New +$57K 0.01% 643

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Abel Hall LLC's HRTX Position: Q1 2026 in Review

Abel Hall LLC reduced its Heron Therapeutics (HRTX) stake by 63% in Q1 2026, selling an estimated $33.9K and leaving 16,907 shares worth $13.5K. The position accounts for ﹤0.01% of the portfolio, ranked #798.

Abel Hall LLC first reported a position in HRTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $60K in Q4 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Abel Hall LLC held 16,907 shares of Heron Therapeutics worth $13.5K as of Q1 2026.
  • Abel Hall LLC sold 29,269 Heron Therapeutics shares in Q1 2026, an estimated $33.9K.
  • Heron Therapeutics made up ﹤0.01% of Abel Hall LLC's portfolio in Q1 2026, its #798 holding.
  • Abel Hall LLC first reported a position in Heron Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Abel Hall LLC's Heron Therapeutics position peaked at $60K in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Abel Hall LLC's 13F filing for Q1 2026, filed 28 Apr 2026.